Purpose Overexpression of CD146 in solid tumors has been linked to disease progression, invasion, and metastasis. We describe the generation of a 64 Cu-labeled CD146-specific antibody and its use for quantitative immunoPET imaging of CD146 expression in six lung cancer models. Methods The anti-CD146 antibody (YY146) was conjugated to 1,4,7-triazacyclononane-triacetic acid (NOTA) and radiolabeled with Cu-NOTA-YY146 was highest in CD146-expressing H460 and H23 tumors, peaking at 20.1 ± 2.86 and 11.6 ± 2.34 %ID/g at 48 h after injection (n = 4). Tumor uptake was lowest in the H522 model (4.1 ± 0.98 %ID/g at 48 h after injection; n = 4), while H4006, A549 and H358 exhibited similar uptake of 64 Cu-NOTA-YY146. A positive correlation was found between tumor uptake of 64 Cu-NOTA-YY146 (%ID/g) and relative CD146 expression (r 2 = 0.98, p < 0.01). Ex vivo biodistribution confirmed the accuracy of the PET data. Conclusion The strong correlation between tumor uptake of 64 Cu-NOTA-YY146 and CD146 expression demonstrates the potential use of this radiotracer for imaging tumors that elicit varying levels of CD146. In the future, this tool may promote enhanced monitoring of therapeutic response and improved patient stratification.
Introduction
Lung cancer is the most commonly diagnosed malignancy worldwide, accounting for more than 13 % of all cancers [1] . North America and Europe continue to display the highest incidence rates of lung cancer with 85 % of lung cancer Haiyan Sun and Christopher G. England contributed equally to this work.
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malignancies being attributed to smoking [2] . In the UK, 20 % of cancer-related deaths were from lung cancer in 2012 [1] . As cancer treatment has become increasingly personalized in the last decade [3, 4] , physicians must determine which patients may benefit from selected therapeutics. For this reason, new tools are needed for imaging malignancies, monitoring therapeutic response, and selecting patients who may benefit from specifically targeted treatments. Molecular imaging has shown great potential in this field with immunoPET imaging currently being the most promising approach [5] . ImmunoPET refers to the utilization of positron emission tomography (PET) in combination with highly specific antibody-based imaging tracers for noninvasively examining tumor phenotypes in vivo with high sensitivity and specificity [6] .
An epithelial-to-mesenchymal transition (EMT) is a biological process that allows epithelial cells to assume a mesenchymal cell phenotype, effectively gaining migratory and invasive properties [7, 8] . EMT is a major mechanism by which malignant cells gain metastatic potential and resistance to apoptosis signaling pathways; thus, EMT is associated with disease progression and diminished patient survival rates [9, 10] . The cell surface protein called CD146 is an activator of EMTs, and overexpression of CD146 in cancer has been shown to downregulate epithelial markers and upregulate mesenchymal markers [11] . CD146 expression is primarily constrained to the intracellular junctions of endothelial cells and is actively involved in several cellular processes including cell-matrix adhesion, cell migration, signal transduction, stem cell differentiation, immune response, and angiogenesis [12] . Additionally, CD146 has low background levels in normal tissue as well as differential expression in metastases and advanced primary tumors, showing its significant potential in cancer therapy [12, 13] . We have previously shown that persistent and specific targeting of CD146 in vivo may be accomplished with the monoclonal antibody known as YY146 [14] .
We have previously reported the production of YY146 using a rapid immunization approach that reduces the production time for antibodies by half compared to standard procedures [14] . Cell hybridomas were prepared from B cells collected from the popliteal lymph nodes of mice immunized with the human CD146 antigen. Subsequently, the most immunoreactive antibody clones were determined by ELISA and further evaluated with YY146 showing optimal properties for continued investigation [14] . To date, the use of YY146 has been limited to brain and gastric cancer, with both diseases showing high levels of CD146 expression and high uptake of YY146 [13] . PET imaging of YY146 allowed visualization of small tumor nodules with high specificity in glioblastoma multiforme [14] . To target gastric cancer, superparamagnetic iron oxide nanoparticles (SPIONs) were coated with dSiO 2 , labeled with the near-infrared fluorescence (NIRF) dye 800 ZW and YY146 ( 800 ZW-SPION@dSiO 2 -YY146) for targeting CD146-expressing gastric cancer [13] . Uptake of 800 ZWSPION@dSiO 2 -YY146 was rapid and specific allowing clear delineation of the tumor at 30 min after injection with the tumor uptake peaking at 24 h after injection. Both of these studies revealed promising results for the use of YY146 for actively targeting CD146-expressing tumors.
In this study, the use of 64 Cu-labeled YY146, an antibody targeting human CD146, for imaging of CD146 expression was investigated in six mouse models of lung cancer. This was accomplished by evaluating CD146 expression in vitro in six human lung cancer cell lines (A549, H358, H522, H4006, H23, and H460) by flow cytometry and western blot studies. The excellent targeting capabilities of 64 Cu-NOTA-YY146 allowed rapid, persistent, and highly specific accumulation in CD146-expressing tumors. Also, a strong correlation was found between relative CD146 expression and tumor uptake of our imaging tracer, providing the initial evidence supporting the future clinical utilization of 64 Cu-NOTA YY146 for enhanced patient stratification or monitoring of therapeutic response.
Materials and methods

Cell culture
The six human lung cancer cell lines A549, NCI-H358 (H358), NCI-H522 (H522), HCC4006 (H4006), H23, and NCI-H460 (H460) were obtained from the American Type Culture Collection (ATCC; Manassas, VA). All six cell lines were grown in a humidified incubator at 37°C in an atmosphere containing 5 % CO 2 using RPMI-1640 medium supplemented with 10 % non-heat-inactivated FBS (Gibco, ThermoFisher Scientific, Waltham, MA) and 1 % penicillinstreptomycin solution (Gibco). Cells were used for studies at about 70 % confluency.
Animal models
All animal studies were conducted under a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee. Subcutaneous xenograft tumors of the six cell lung cancer cell lines (A549, H358, H522, H4006, H23, and H460) were induced in 5-week-old female athymic nude mice (Crl: NU(NCr)-Foxn1 nu ; Envigo, Alconbury, UK). For implantation, 100 μL (1 × 10 6 cells) of a 1:1 mixture of lung cancer cells and Matrigel matrix basement membrane (Corning, Corning, NY) was subcutaneously injected into the lower flank of the mice. Tumor size was monitored three times weekly, and the animals were used for imaging once the tumor had reached 5 -10 mm in diameter, which was approximately 3 -4 weeks after implantation.
NOTA conjugation and radiolabeling
The detailed procedures for NOTA conjugation and 64 Cu labeling have been previously reported [14] . Briefly, a PBS solution of 2 -3 mg YY146 was adjusted to pH 8.5 -9.0 with 0.1 M Na 2 CO 3 . Next, p-SCN-Bn-NOTA (NOTA; Macrocyclics, Dallas, TX) was dissolved in DMSO and immediately added to the antibody solution at a 20:1 molar ratio. The pH was readjusted to 9.0, and the reaction was left to proceed for 2 h at 25 -30°C. NOTA-YY146 was purified using size exclusion PD-10 columns (GE Healthcare, Aurora, OH) with PBS (pH 7.0) as the mobile phase. High specific activity (>5 Ci/μmol at the end of bombardment) Cu-NOTA-YY146, using PD-10 columns with PBS as the mobile phase. The radioactive fractions containing 64 Cu-NOTA-YY146 were collected and filtered through a 0.2-μm filter for animal injection.
Flow cytometry
The binding and immunoreactivity of YY146 and NOTA-YY146 toward CD146 expressed in six lung cancer cell lines (H4006, H522, H460, H358, H23, and A549) was determined by flow cytometry. Cells were harvested and suspended in icecold PBS (pH 7.4) with 1 % BSA at a concentration of 1 × 10 6 cells/mL. Cells were incubated with PBS, 5 μg/mL of YY146, 25 μg/mL of YY146, 5 μg/mL of NOTA-YY146, or 25 μg/ mL of NOTA-YY146 for 30 min at 25 -30°C. After incubation, cells were washed three times with ice-cold PBS and centrifuged at 150 × g for 5 min. Next, cells were incubated with the FITC-labeled goat anti-mouse secondary antibody (5 μg/mL) for 30 min at 25 -30°C. After incubation with the secondary antibody, the binding efficiency was analyzed using a MACSQuant cytometer (Miltenyi Biotech, Bergisch Gladbach, Germany) and mean fluorescence intensities were processed using FlowJo analysis software (Tree Star, Inc., Ashland, OR).
Saturation binding assay
A saturation binding assay was used to calculate the receptor density of CD146 in lung cancer cells. H460 cells were seeded in a 96-well plate at 1 × 10 6 cells per well. 64 Cu-NOTA-YY146 was mixed with nonradiolabeled YY146 at a ratio of 1:1,000. Then the antibody solution was added to each well (0.1 μCi per well) with increasing concentrations (0.03 -100 nM). After incubation at room temperature for 2 h, cells were washed twice with 1 × PBS (containing 0.1 % BSA), then harvested and the activity determined with a gamma counter. To determine the amount of nonspecific binding, 1 μmol nonradiolabeled YY146 was added. After incubation for 2 h at room temperature, cells were washed twice with 1 × PBS (containing 0.1 % BSA) and analyzed with a gamma counter. Based on specifically bound ligands, the K d and B max values were determined, and the receptor density on H460 cells was determined using GraphPad Prism software (La Jolla, CA).
Western blot
CD146 expression was determined by western blot using standard techniques. Once the lung cancer cell lines had reached 70 % confluency, the cells were washed with icec o l d P B S . N e x t , t h e c e l l s w e r e l y s e d u s i n g radioimmunoprecipitation assay (RIPA) buffer (Boston BioProducts, Ashland, MA) supplemented with a 1:100 protease inhibitor cocktail (Halt inhibitor cocktail; ThermoFisher Scientific, Carlsbad, CA) for 15 min at 4°C. Cells were scraped, and the lysis solution was centrifuged at 13,000 × g for 10 min at 4°C. The supernatant was removed, and the protein concentration was measured using the Pierce™ Coomassie (Bradford) protein assay kit (ThermoFisher Scientific). Next, 30 μg of total protein was loaded into the corresponding wells of a 4 -12 % Bolt Bis-Tris Plus gel (ThermoFisher Scientific) in addition to the Chameleon Duo molecular weight ladder (LI-COR Biosciences, Lincoln, NE). Following electrophoresis at 120 mV for 45 min at 4°C, proteins were transferred to a nitrocellulose membrane using the iBlot 2 system (ThermoFisher Scientific). The membrane was blocked with Odyssey blocking buffer (PBS; LI-COR Biosciences) for 2 h at 27°C. The membrane was placed in the iBind western device (ThermoFisher Scientific) and the primary and secondary antibody solutions and washes were put in the corresponding chambers. The mousederived monoclonal CD146 antibody (Santa Cruz, Dallas, TX) was diluted at 1:100 and rabbit β-actin (LI-COR Biosciences) was diluted at 1:400 using the iBind fluorescent detection solution kit (ThermoFisher Scientific) according to the manufacturer's protocol. Similarly, the secondary antibodies (donkey anti-mouse IRDye 680RD and donkey anti-human 800CW) were diluted at 1:1,500 and placed into their corresponding chambers. The membrane was left in the iBind system for 12 h at 4°C before the membrane was removed for scanning using the LI-COR Odyssey infrared imaging system (LI-COR Biosciences).
PET imaging and image analysis
PET scans were performed at 4, 24, and 48 h after mice were injected with 64 Cu-NOTA-YY146 on the Inveon microPET rodent model scanner (Siemens Medical Solutions, Malvern, PA). Anesthesia was induced and maintained with 2 % isoflurane, and mice were placed in the scanner in the prone position for imaging. At each time-point, 20 million coincidence events were acquired per mouse for every static PET emission scan (energy window 350 -650 keV, time window 3.432 ns, resolution 1.5 mm). PET images were reconstructed using the Inveon Acquisition Workplace (Siemens Medical Solutions). Quantitative region-of-interest (ROI) analysis was carried out on PET images corrected for attenuation and decay, and the uptake of activity in tissues is presented as the percentage of injected dose per gram (%ID/g).
Correlation between CD146 expression and tumor uptake of 64 Cu-NOTA-YY146
The CD146/β-actin ratio of CD146 expression and the relative expression of CD146 were correlated with the tumor uptake of 64 Cu-NOTA-YY146 in the six lung cancer-derived tumor models. Origin 2015 software (Origin Labs, Northampton, MA) was used to plot the average values for uptake of 64 Cu-NOTA-YY146 in each model (n = 4 or 5) against the quantified levels of CD146 determined by western blot studies. A linear fit was applied to the graph to determine the strength of the association between tumor uptake of our imaging probe and expression levels, also known as the correlation coefficient (r 2 ).
Ex vivo biodistribution studies
Biodistribution studies were performed to validate the PET data after the final PET scans 48 h after injection. Mice were killed by CO 2 asphyxiation before the blood, tumor, and all the main organs/tissues were collected and weighed. The activity in tissues was counted in an automated γ-counter (PerkinElmer, Waltham, MA), and the accumulated activity values were calculated and are reported as %ID/g (mean ± SD).
Immunofluorescence staining
Immunofluorescence staining was conducted following a previously described methodology to evaluate the expression of CD146 and CD31 in tumor sections of six lung cancer models [15] . Briefly, tumors extracted after the last PET imaging timepoint (48 h) and embedded in Tissue-Tek optimal cutting temperature (O.C.T.) compound (Sakura Finetek, Torrance, CA). Histologic sectioning of tumor tissue was provided by the University of Wisconsin Carbone Cancer Center Experimental Pathology Laboratory. Frozen tissue slices of 5-μm thickness were fixed with cold acetone for 10 min and dried in the air for 30 min. The slides were rinsed with PBS and then blocked with 10 % donkey serum for 30 min at 25°C. Next, the slides were incubated overnight at 4°C with 1 mL of YY146 (10 μg/mL) and 1 mL of rat anti-mouse CD31 (BD BioSciences, San Jose, CA) antibody (2 μg/mL). AlexaFluor 488 -labeled goat anti-mouse antibody and Cy3-labeled donkey anti-rat antibodies were used to visualize CD146 and CD31, respectively. A coverslip was applied to each slide using Vectashield mounting medium for fluorescence microscopy with DAPI (4′,6-diamidino-2-phenylindole; Vector Laboratories, Burlingame, CA). All images were acquired using an A1R confocal microscope (Nikon). All images were acquired with a Nikon Digital Eclipse C1 plus microscope equipped with three excitation lasers at 488 nm, 546 nm, and 633 nm (Nikon Instruments, Melville, NY).
Tissue microarray analysis
The FDA normal human organ tissue array (FDA993; US Biomax, Inc., Rockville, MD) and multitype lung cancer and normal tissue with TNM and grade tissue microarray (LCM501; US Biomax) were stained for CD146 expression. Briefly, the slides were deparaffinized through xylene and ethanol washes before antigen retrieval using Vector antigen unmasking solution (Vector Laboratories). Next, slides were blocked with 2.5 % normal horse serum of the Impress reagent kit anti-mouse IgG (Vector Laboratories) for 30 min at room temperature. The slides were incubated with the primary anti-CD146 antibody (NBP2-44512; Novus Biologicals, Littleton, CO) overnight at 4°C. The slides were washed with PBS and blocked with 3 % H 2 O 2 for 5 min. Next, the slides were incubated with the ImmPACT DAB reagent (Vector Laboratories) for 45 s. The slides were rinsed 0.05 M sodium bicarbonate solution (pH 9.6) for 10 min and then DAB enhancement solution (Vector Laboratories, Burlingame, CA) was added for 20 s and the slides washed and counterstaining with hematoxylin QS (Vector Laboratories) for 20 s. The slides were washed several times in water and coverslipped for microscopic analysis. Staining intensity was determined using ImageJ and tissues were categorized as 0 for no positive staining, 1 for light positive staining, 2 for moderate positive staining, and 3 for high positive staining. To calculate the percent positive, 0 and 1 were considered as CD146-negative, while 2 and 3 were considered CD146-positive.
Statistical analysis
Quantitative data are expressed as mean ± standard deviation (SD). Statistical analyses were performed using a Student's t test or one-way analysis of variance (ANOVA). A confidence interval of 95 % was selected with p < 0.05 considered statistically significant.
Results
Binding of YY146 and NOTA-YY146 to CD146
The binding of YY146 to CD146-expressing cells was analyzed by flow cytometry (Fig. 1) . Cell lines were incubated with YY146 (5 or 25 μg/mL), NOTA-conjugated YY146 (5 or 25 μg/mL), secondary antibody alone, or PBS as a negative control. H460 and H23 cells displayed enhanced fluorescence signal when incubated with both YY146 and NOTA-YY146, indicative of elevated CD146 expression in these cell lines. Also, there were no appreciable differences in the binding affinity of NOTA-YY146 or YY146 alone, suggesting that NOTA conjugation did not affect the immunoreactivity of YY146 to CD146 at either concentration. A549 and H4006 cells showed similar results to H460 and H23, but to a lesser degree which suggests lower levels of CD146 expression in these two cell lines. H358 cells showed a slight increase in fluorescence signal when incubated with 25 μg/mL of YY146 or NOTA-YY146, but the lower concentration of YY146 or NOTA-YY146 (5 μg/mL) failed to provide a signal difference. This suggests that H358 cells express CD146 at low levels. Lastly, H522 cells did not display an increase in fluorescence signal when incubated with YY146 or NOTA-YY146, indicating that this cell line may lack CD146 or the cell line may display basal levels of CD146 expression.
CD146 expression in lung cancer cell lines
The expression of CD146 was examined in six human lung cancer cell lines. Western blot results were quantified using a protocol provided by LI-COR Biosciences [16] . The ratio of CD146 to β-actin was calculated in addition to the relative expression of CD146 (Fig. 2 and Table S1 ). The ratio of CD146 to β-actin was obtained by normalizing the band intensities of CD146 to those of β-actin, while relative CD146 expression is shown as CD146 band intensities normalized to 1.00. Two bands were seen in each western blot at about 110 kDa corresponding to CD146, while β-actin was visible at 38 kDa (Fig. 2a) . In each case, the band for H460 cells showed the highest signal (relative expression of CD146 is normalized to 1.00), indicative of the highest CD146 expression (n = 3; Fig. 2b, c) . The H522 and H4006 cells showed similar expression levels of CD146 with relative expression values of 0.34 ± 0.05 and 0.25 ± 0.02, respectively (n = 3; Fig. 2c ). H23 cells showed lower levels of relative CD146 expression (0.18 ± 0.03), while A549 and H358 cells showed background or minimal expression of CD146 with relative expression values of 0.06 ± 0.01 and 0.07 ± 0.01, respectively (n = 3; Fig. 2c ). CD146 expression receptor density was calculated for H460 cells, which expressed the highest levels of CD146, and was about 125,000 receptors per cell (Fig. S1 ). Cu-NOTA-YY146 was monitored in lung cancer-derived mouse models for 48 h after injection. Representative maximum intensity projection images from each group of tumor-bearing mice at 4, 24, and 48 h after injection are shown in Fig. 3 . PET imaging revealed different degrees of 64 Cu-NOTA-YY146 between the six mouse models, with H460 and H23 tumors showing the highest tracer accumulation. Most tumor models, excluding H358 and H522, showed prominent uptake of 64 Cu-NOTA-YY146 that allowed clear delineation of tumor boundaries. All mouse models displayed similar blood uptake suggesting that the antibody was highly stable in the circulation. Also, high tracer accumulation in the liver was indicative of hepatic clearance and possible hepatobiliary circulation that antibodies undergo for clearance.
The ROI quantitative analysis of PET images revealed high activity in the blood pool that steadily declined throughout the study for each tumor-derived model (Fig. 4 and Tables S2-S4) . At 4 h after injection, activity in the blood pool was between 17.5 ± 1.49 and 20.5 ± 0.78 %ID/g (n = 4; Fig. 4b ). Initially high levels of activity in liver tissues have been linked to the slow clearance shown by intact IgG antibodies [17] . Both the liver and spleen showed high levels of activity at 4 h after injection, but the levels gradually decreased between 24 and 48 h after injection (Fig. 4) . Tumor accumulation of 64 Cu-NOTA-YY146 was highest in the H460 tumor model at 4, 24, and 48 h after injection with activity levels of 10.5 ± 1.97, 17.4 ± 2.41, and 20.1 ± 2.86 %ID/g, respectively (n = 4; Fig. 4a ). Activity in the tumor increased in each cell line, but accumulation in CD146-negative cell lines suggests a The tumor-to-muscle activity ratios were calculated to compare the six different models (Fig. S2) . Several statistically significant differences were found among the six tumor models, with H460 tumors showing statistically significant differences in activity accumulation compared with each of the other tumor models at 48 h after injection (n = 4; Fig. S2 ). Also, statistically significant differences were found between the tumor-to-muscle ratio for H23 tumors and the ratios for the three other tumor models (H4006, H358, and H522) at 48 h after injection (n = 4).
Correlation between CD146 expression and uptake of 64 
Cu-NOTA-YY146
Quantitative data from the ROI analysis and western blot studies were used to investigate the correlation between the uptake of 64 Cu-NOTA-YY146 (%ID/g) and CD146 expression levels (Fig. 5) . A strong linear correlation was found between the tumor accumulation of 64 Cu-NOTA-YY146 and the CD146/β-actin ratio at 48 h after injection (r 2 = 0.96, p < 0.01; Fig. 5a ). Similarly, tumor accumulation of 64 Cu-NOTA-YY146 and relative CD146 expression showed a strong linear correlation at 48 h after injection (r 2 = 0.98, p < 0.01; Fig. 5b ).
Biodistribution of 64
Cu-NOTA-YY146
Ex vivo biodistribution was carried out after the final PET imaging time-point at 48 h after injection to validate the uptake values determined from the PET ROI analysis (Fig. 6 ). At this time, mice were killed, and the tumor, blood and major organs were collected for gamma counting. Biodistribution of 64 Cu-NOTA-YY146 in tumor-bearing mice revealed high blood uptake that was similar among all six tumor models, confirming the stability of the imaging tracer in serum (n = 4; Table S5 ). Elevated uptake of 64 Cu-NOTA-YY146 was also found in the liver, kidney, and spleen tissues with similarities among the tumor models. Several organs and tissues displayed minimal or background levels of activity, including the pancreas, stomach, bone, muscle, and brain. Also, biodistribution studies corroborated the variations in tumor uptake of 6 4 Cu-NOTA-YY146 originally established by PET imaging. A statistically significant difference in tumor uptake was found between H460 and the other cell line-derived tumor models ( Fig. 6 ; n = 4; p < 0.05). Also, H23 tumors showed higher uptake of 64 Cu-NOTA-YY146 than H4006, A549, H358, and H522 tumors ( Fig. 6 ; n = 4; p < 0.05). Overall, ex vivo biodistribution studies provided physical evidence supporting the accuracy of PET imaging analysis for quantifying the biodistribution of 64 Cu-NOTA-YY146 in vivo, providing deeper insight into the movement of highly specific radiolabeled tracers injected into tumorderived mouse models.
Immunofluorescence costaining of CD146 and CD31
Ex vivo immunofluorescence staining of tumor sections for CD146 and CD31 provided further insight into the spatial location of CD146 in each tumor model while also offering details regarding tumor vasculature. The cell lines were shown to express CD146 by immunofluorescence staining (Fig. 7) . Expression of CD146, as shown in the green fluorescence channel, was highest in H460 tumor sections, closely followed by H23. The A549, H522, and H358 tumor sections exhibited low fluorescence signal indicating median to low levels of CD146 expression. Lastly, H4006 tumor sections showed no fluorescence staining of CD146 indicating minimal CD146 expression. In addition to CD146, CD31 was stained for visualization of tumor vasculature. Each tumor model showed similar levels of vasculature, yet the vasculature appeared more organized in some tumor models including H460, H23, A549, and H4006 (Fig. 7) . Together, these results from the immunofluorescence staining of ex vivo tumor sections further verify the findings from in vivo assays, PET imaging, and biodistribution studies.
CD146 staining of normal human tissues and human lung malignancies
Tissue microarrays were used to examine the overall expression of CD146 in both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) (Fig. S3) . Of the NSCLC, 74.4 % showed high CD146 expression, while only 20.0 % of SCLC showed high CD146 expression. In addition, CD146 was expressed in several healthy tissues, including the tonsils, stomach, kidneys, larynx, uterus, liver, and some nerve tissues (Fig. S4) . These results were in agreement with observations reported in the Human Protein Atlas [18] . 
Discussion
Despite significant diagnostic and therapeutic advances, lung cancer remains the leading cause of cancer-related death worldwide [19] . As lung tumors display phenotypic and genotypic heterogeneities between patients [20, 21] , it has become increasingly important for physicians to construct individualized treatment plans effective in each patient. In the last decade, the role of genomic screening in cancer clinics has become conventional, as studies have shown that over 60 % of patients with lung cancer display one or more specific mutations [22] . The results from genomic testing may have a significant impact on individual treatment plans. For example, patients with an epidermal growth factor receptor mutation show a higher response rate to erlotinib [23] , while crizotinib is considered in patients with the fusion gene echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) [24] . Genomic screening is an extremely invasive procedure requiring tissue biopsies; thus, researchers are assessing newer technologies, such as molecular imaging, for noninvasively assessing tumor phenotypes in patients.
Recently, CD146 overexpression has been evaluated in high-grade gliomas by molecular imaging [14] . While the antibody showed high specificity in CD146-expressing gliomas, the study did not show a correlation between CD146 expression and tumor uptake. As antibody tracers are specifically targeted to their corresponding protein, previous studies have shown that a receptor density of greater than 10 5 receptors per cell is required for effective targeting [25, 26] . CD146 has been found to be expressed in 51 % of human lung cancer malignancies, correlating with shortened survival in patients with adenocarcinoma [27] . In this study, microarray analysis showed that CD146 was expressed in 74.4 % of NSCLC samples, yet CD146 was expressed in only 20 % of SCLC samples (Fig. S3) . These findings corroborate those of another study showing that 5-year survival rates of patients with tumors negative and positive for CD146 were 84 % and 50 %, respectively [28] . For these reasons, CD146 has become an attractive biomarker for prediction of patient survival, for stratification of cancer patients, and for the development of targeted therapies. While an imaging agent based upon CD146 alone may have limited value for clinically detecting all lung malignancies, it may provide both diagnostic and monitoring benefits in many patients. In addition, imaging biomarkers provide an alternative to highly invasive tissue biopsies.
In this study, we hypothesized that tumor uptake of 64 Cu-NOTA-YY146 would strongly correlate with the tumor expression of CD146. Quantification of the protein bands on western blot provided numerical values for both relative expression and β-actin-normalized expression (Table S1 ). CD146 expression in terms of relative values showed the strongest correlation with tumor uptake of 64 Cu-NOTA-YY146 (r 2 = 0.98, p < 0.01; Fig. 5b ), while β-actinnormalized values provided a slightly weaker correlation (r 2 = 0.96, p < 0.01; Fig. 5a ). As cell lines may display marginally different levels β-actin [29] , it was not alarming that the relative expression showed a stronger correlation.
Radiolabeling of YY146 with 64 Cu required the use of NOTA, which is conjugated to the antibody via lysine residues. As shown by flow cytometry and immunofluorescence staining studies (Figs. 1 and 7) , conjugation of this chelator did not impair the binding of YY146 to CD146. This suggests that the lysine residues involved in the conjugation chemistry are not involved in the binding sites of YY146 [30] [31] [32] [33] . Overall, PET imaging revealed that tumor uptake of 64 Cu-NOTA-YY146 was persistent, prominent, and highly specific.
Tumor accumulation of the antibody tracer was highest in H4006 and H23 tumor models at 48 h (20.1 ± 2.86 and 11.6 ± 2.34 %ID/g, respectively; n = 4; Fig. 4a) . While it is possible that passive accumulation of the antibody tracer could have contributed to these values as a result of the enhanced permeability and retention effect, previous studies have shown that off-target accumulation usually occurs faster (<24 h) and tumors will show a slow decrease in activity [34, 35] . In our study, the maximum tumor uptake of 64 Cu-NOTA-YY146 occurred at the final time-point (48 h), showing a plateau in activity with no leakage or decline (Fig. 4) . Uptake of the Fig. 7 Immunofluorescence costaining of tumor sections for CD146 and CD31. The two primary antibodies, YY146 (green) and CD31 (red), were visualized with AlexaFluor 488 -labeled goat anti-mouse and Cy3-labeled donkey anti-rat secondary antibodies. Cell nuclei were stained with DAPI (blue). ×400 tracer in the blood pool was initially high ranging from 17.4 ± 1.12 to 20.5 ± 0.78 %ID/g at 4 h after injection (n = 4) with a steady decline over time (Fig. 4b) . As antibodies may circulate for up to 45 days in vivo [36] , we expected to see high blood activity levels confirming the enhanced stability of our tracer for in vivo applications.
Conclusion
In this study we investigated the uptake of 64 Cu-labeled YY146, an antibody specifically targeting human CD146, in six mouse models of human lung cancer. PET imaging revealed high uptake of 64 Cu-NOTA-YY146 in CD146-positive tumors while tumor models with low CD146 expression showed significantly less tumor uptake. Also, there was a strong linear correlation between tumor uptake of 64 Cu-NOTA-YY146 and relative expression of CD146 in the tumor cell lines (r 2 = 0.98, p < 0.01), reinforcing the potential use of immunoPET imaging for quantitatively assessing CD146 expression in vivo. Since CD146 is expressed in many cancers, we believe that CD146-based tracers may show great clinical utility in the future, as this versatile imaging biomarker may assist in diagnosing and staging cancers, monitoring the response of patients to therapy, and investigating novel therapeutic and diagnostic antibodies.
